On November 30, 2017, Mr. Geoffrey Wolf resigned as a member of the Board of Directors (the Board") of Opiant Pharmaceuticals, Inc. (the Company"), and any committees of the Board, as well as any officer or other positions he held with the Company, effective November 30, 2017. Mr. Wolf resigned as a result of a dispute between Mr. Wolf and the Company regarding the Company's historical failure to register shares underlying certain options and warrants previously granted to Mr. Wolf, which registration was remedied on November 27, 2017. At the time of his resignation, a dispute also had arisen between the Company and Mr. Wolf regarding potential violations of Company policy. Mr. Wolf disputes any allegation that he violated any Company policy.